The U.S. Food and Drug Administration (FDA) approved giredestrant (Wilserdly), a once-daily pill, on Monday. It’s meant to be taken with the cancer drug everolimus.
The pairing is for adults with estrogen receptor (ER)-positive, HER2-negative breast cancer that has grown into nearby tissue or spread to other parts of the body.
ER-positive cancers feed on the hormone estrogen to grow. HER2-negative means the tumor doesn’t make high levels of a growth protein called HER2.
Over time, though, many of these tumors develop a change in a gene called ESR1 that helps them slip past hormone drugs. Up to 40% of patients with this type of advanced breast cancer develop ESR1 mutations, Roche said in a news release.